Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. J of Skin [Internet]. 2022 Nov. 16 [cited 2026 Apr. 20];6(6):s49. Available from: https://skin.dermsquared.com/skin/article/view/1804